The Alliance to Save America’s 340B Program is a partnership of community health centers, patient and consumer advocates, and leaders from the biopharmaceutical industry working to ensure the 340B program supports true safety-net providers and the communities they serve.

2022年10月20日 · Medicare Administrative Contractors will pay 340B hospitals Average Sales Price plus 6%, rather than ASP minus 22.5%, for all CY 2022 drug claims with modifier “JG,” CMS confirmed for AHA yesterday.

2023年11月2日 · Section 340B of the Public Health Service Act (340B) allows participating hospitals and other providers to purchase certain covered outpatient drugs or biologicals (hereinafter referred to collectively as “drugs”) from manufacturers at discounted prices.

2023年1月13日 · OPPS Payment for 340B Drugs. In the CY 2018 OPPS/ASC final rule, CMS reexamined whether it should pay the average sales price (ASP) plus 6% for drugs acquired through the 340B Program, as 340B hospitals acquire the drugs at steep discounts.

District of Columbia vacated the differential payment rates for 340B-acquired drugs in the Calendar Year (CY) 2022 Outpatient Prospective Payment System (OPPS) final rule on September 28, 2022. Therefore, CMS cannot apply the Average Sales Price (ASP) minus 22.5%

Medicare historically reimbursed all hospitals under the outpatient prospective payment system (OPPS) for separately payable drugs at average sales price (ASP) plus 6 percent.

Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to eligible health care organizations including community health centers, children’s hospitals, hemophilia treatment centers, critical access hospitals (CAHs), sole community hospitals (SCHs)...

The Alliance to Save America’s 340B Program (ASAP 340B) supports an approach that includes all the policy areas outlined below, with statutory changes that codify both contract pharmacy arrangements and critical changes

2023年7月7日 · Today, the Centers for Medicare & Medicaid Services (CMS) released a long-awaited proposed rule detailing how it intends to repay hospitals for 340B Drug Pricing Program underpayments. The proposed rule is the result of CMS’s cuts to the 340B program's reimbursement in 2018, which dropped payment from average sales …

2023年11月3日 · The Department of Health and Human Services (HHS) finalized its rule detailing how it will repay hospitals for 340B Drug Pricing Program underpayments. The final rule stems from the Supreme Court’s invalidation of cuts by the Centers for Medicare & Medicaid Services (CMS) to 340B reimbursement in 2018, which dropped payment from average sales ...